SCIENCE 37 HOLDINGS INC (SNCE)
US8086442071 - Common Stock
Overall SNCE gets a fundamental rating of 2 out of 10. We evaluated SNCE against 58 industry peers in the Life Sciences Tools & Services industry. The financial health of SNCE is average, but there are quite some concerns on its profitability. SNCE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SNCE had negative earnings in the past year.
In the past year SNCE has reported a negative cash flow from operations.
1.2 Ratios
SNCE has a Return On Assets of -164.66%. This is amonst the worse of the industry: SNCE underperforms 98.31% of its industry peers.
SNCE's Return On Equity of -241.10% is on the low side compared to the rest of the industry. SNCE is outperformed by 88.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| ROIC | N/A |
ROA(3y)-44.02%
ROA(5y)N/A
ROE(3y)-71.84%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SNCE (29.75%) is worse than 72.88% of its industry peers.
SNCE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNCE has more shares outstanding than it did 1 year ago.
SNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SNCE has an Altman-Z score of -5.81. This is a bad value and indicates that SNCE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNCE (-5.81) is worse than 93.22% of its industry peers.
SNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.81 |
ROIC/WACCN/A
WACC11.9%
2.3 Liquidity
A Current Ratio of 4.17 indicates that SNCE has no problem at all paying its short term obligations.
The Current ratio of SNCE (4.17) is better than 62.71% of its industry peers.
SNCE has a Quick Ratio of 4.17. This indicates that SNCE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.17, SNCE is in the better half of the industry, outperforming 67.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
The earnings per share for SNCE have decreased strongly by -881.08% in the last year.
The Revenue for SNCE has decreased by -19.21% in the past year. This is quite bad
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-429.41%
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-8.37%
3.2 Future
SNCE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.15% yearly.
Based on estimates for the next years, SNCE will show a quite strong growth in Revenue. The Revenue will grow by 14.73% on average per year.
EPS Next Y-72.66%
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
EPS Next 5YN/A
Revenue Next Year-14.69%
Revenue Next 2Y-4.18%
Revenue Next 3Y3.19%
Revenue Next 5Y14.73%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SNCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNCE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
5. Dividend
5.1 Amount
No dividends for SNCE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCIENCE 37 HOLDINGS INC
NASDAQ:SNCE (3/11/2024, 6:05:35 PM)
After market: 5.7203 -0.03 (-0.52%)5.75
+0.02 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap34.67M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.66% | ||
| ROE | -241.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-72.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y